Status:
COMPLETED
Enhancing Breast Milk Production With Domperidone in Mothers of Preterm Neonates
Lead Sponsor:
Sunnybrook Health Sciences Centre
Conditions:
Low Milk Supply
Eligibility:
FEMALE
18-45 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of Domperidone in those mothers who are identified as having difficulty with breast milk production to meet the nutritional needs of th...
Detailed Description
It is widely acknowledged that recent perinatal and neonatal technological advances (eg. assisted ventilation, surfactant, antenatal corticosteroids) have greatly enhanced the survival rate of very lo...
Eligibility Criteria
Inclusion
- mothers of a preterm infant born \< 30 completed weeks gestation (23 0/7-29 6/7 weeks)
- postpartum period of 7-21 days
- mechanically pumping a minimum average of 6 times a day in the 4-7 days prior to enrollment
- experiencing inadequate milk supply defined as providing \< 100% of the average of the daily nutritional intake during the previous 72-hour period prior to enrollment based on a fluid intake of 250 mL/kg/d or experiencing a clinical reduction of approximately 20% from a peak volume during the previous 72-hour period prior to enrollment
Exclusion
- history of known or suspected cardiac dysrhythmias (tachyarrhythmia, Q-Tc prolongation) or currently on an anti-arrhythmic medication
- currently experiencing mastitis
- previous breast surgery, including augmentation or reduction, nipple piercing and/or the use of nipple rings/studs within the last year, or any reduction
- known chronic or debilitating illness, known abnormal liver function or gastric abnormalities gastrointestinal that will be exacerbated by the use of a prokinetic, examples include hemorrhage or blockage, actively treated with acid reflux which requires treatment for greater than 5 days and includes H2 blockers (occasional use of H2 blockers for heartburn or mild acid reflux is not considered an exclusion) and HIV
- known to have a prolactin-releasing pituitary tumor
- receiving medications known to alter the metabolism and pharmacokinetics of domperidone (eg. oral "azole" antifungals, erythromycin antibiotics, monoamine oxidase inhibitors (MAO) inhibitors) or medications that have dopaminergic or antidopaminergic activity or affect prolactin levels
- mothers of higher order pregnancies (triplet, or more)
- currently smoking 6 or more cigarette per day as reported by the mother
Key Trial Info
Start Date :
May 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT01512225
Start Date
May 1 2012
End Date
March 1 2016
Last Update
April 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5